Back
Codexis, Inc. 10K Form
Sell
47
CDXS
Codexis, Inc.
Last Price:
$1.82
Seasonality Move:
-4.56%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | CDXS/Codexis, Inc. Quarterly |
| 2023-11-03 | 10Q | CDXS/Codexis, Inc. Quarterly |
| 2023-08-03 | 10Q | CDXS/Codexis, Inc. Quarterly |
| 2023-05-04 | 10Q | CDXS/Codexis, Inc. Quarterly |
| 2022-11-04 | 10Q | CDXS/Codexis, Inc. Quarterly |
| 2022-08-05 | 10Q | CDXS/Codexis, Inc. Quarterly |
Receive CDXS News And Ratings
See the #1 stock for the next 7 days that we like better than CDXS
CDXS Financial Statistics
Sales & Book Value
| Annual Sales: | $70.4M |
|---|---|
| Cash Flow: | $19.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.56 |
| Price / Book: | 3.41 |
Profitability
| EPS (TTM): | -0.51810 |
|---|---|
| Net Income (TTM): | $-44M |
| Gross Margin: | $56M |
| Return on Equity: | -84.16% |
| Return on Assets: | -31.96% |
Codexis, Inc. Earnings Forecast
Key Codexis, Inc. Financial Ratios
-
The Gross Profit Margin over the past 20 years for CDXS is 79.49%.
-
The Selling, General & Administrative Expenses for CDXS have been equal to 66.88% of Gross Profit Margin.
-
The Research & Development expenses have been 68.45% of Revenue.
-
The Net Earning history of CDXS is -62.47% of Total Revenues.
-
Per Share Earnings over the last 20 years have been positive in 8 years.
Codexis, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Life Sciences Tools & Services |
| Sector: | Health Care |
| Current Symbol: | CDXS |
| CUSIP: | 192005 |
| Website: | codexis.com |
Debt
| Debt-to-Equity Ratio: | 1.45 |
|---|---|
| Current Ratio: | 3.82 |
| Quick Ratio: | 3.53 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CDXS Technical Analysis vs Fundamental Analysis
Sell
47
Codexis, Inc. (CDXS)
is a Sell
Is Codexis, Inc. a Buy or a Sell?
-
Codexis, Inc. stock is rated a SellThe current Codexis, Inc. [CDXS] share price is $1.82. The Score for CDXS is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.